Larazotide Acetate
An octapeptide that restores intestinal tight junction integrity by antagonizing zonulin, the protein that regulates paracellular permeability.
Also known as: AT-1001, Tight Junction Regulator
Important: This content is for informational and research purposes only and is not intended for human or veterinary use. Consult your physician for health-related guidance and laboratory monitoring.
How It Works
Blocks zonulin-mediated tight junction disruption via MLCK inhibition. Promotes proper localization of claudin-4, occludin, ZO-1, and E-cadherin at epithelial junctions.
Key Benefits
- ✓Restores intestinal barrier function
- ✓Reduces intestinal permeability
- ✓Decreases symptom days by 26-31%
- ✓Supports tight junction protein assembly
- ✓Prevents gluten-induced barrier breakdown
Dosing Protocols
Beginner / Intermediate
Dose
0.5 mg
Frequency
Three times daily with meals
Cycle Length
4-8 weeks
Notes
Take with food for optimal mucosal contact
Advanced
Dose
1 mg
Frequency
Three times daily with meals
Cycle Length
8-12 weeks
Notes
Higher doses show no additional benefit; lower dose is optimal
Side Effects & Safety
Common Side Effects
- Headache (paradoxically reduced at optimal dose)
- Mild GI symptoms
- Urinary tract infection (mechanism unclear)
- Overall safety profile excellent
Contraindications
- Pregnancy and lactation
- Active severe infection
- Inflammatory flare requiring immunosuppression
Stacking & Synergies
These compounds have complementary mechanisms and may enhance results when used together.
Key Takeaway
Seal your gut: Larazotide restores tight junction integrity for rapid barrier restoration.
Research Disclaimer: This content is for informational and research purposes only. It is not medical advice. These products are not approved by the FDA for human consumption. Consult a qualified healthcare provider before starting any new protocol. The information provided is based on preclinical research and anecdotal reports and has not been formally evaluated in randomized controlled trials.